🇺🇸 FDA
Patent

US 11780839

Compounds for treating Huntington's disease

granted A61PA61P25/28

Quick answer

US patent 11780839 (Compounds for treating Huntington's disease) held by PTC THERAPEUTICS, INC. expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
PTC THERAPEUTICS, INC.
Grant date
Tue Oct 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61P, A61P25/28